Since several AKT/mTOR pathway inhibitors have been shown to be effective for endocrine-resistant breast cancer cell lines [32], we decided next to investigate if the in vivo derived AKT gene module would be able to predict the response to drugs targeting the AKT/mTOR pathway. This evidence concerns the gene AKT1 and breast carcinoma.